KPCB and affiliates have supplied a $35m series A extension for University of Pennsylvania spinout Tmunity, after the institution backed a $100m close in January.
Tmunity Therapeutics, a US-based immunotherapy spinout from University of Pennsylvania, grew its series A round to $135m yesterday after securing a $35m extension from Kleiner Perkins Caufield and Byers and unnamed affiliates.
The spinout secured a $100m initial tranche in January 2018 from investors including University of Pennsylvania and Parker Institute for Cancer Immunotherapy.
The first close also featured biopharmaceutical firm Gilead Sciences, insurance provider Ping An, pharmaceutical company Eli Lilly and cellular research company Be The Match BioTherapies.
…
